Aripiprazole augmentation in clozapine-treated patients with refractory schizophrenia: An 8-week, randomized, double-blind, placebo-controlled trial

Journal of Clinical Psychiatry

Volumn 69, Issue 5, 2008, Pages 720-731

  Chang, Jae Seung ^a,d   Ahn, Yong Min ^b,c   Park, Hye Jean ^b   Lee, Kyu Young ^b,e   Kim, Se Hyun ^b   Kang, Ung Gu ^b,c   Kim, Yong Sik ^b,c  

^a Seoul Eunpyeong Hospital   (South Korea)

^b Seoul National University Hospital   (South Korea)

^c Seoul National University College of Medicine   (South Korea)

^d Seoul National University Bundang Hospital   (South Korea)

^e Eulji General Hospital   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; BENZODIAZEPINE; CHLORPROMAZINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLOZAPINE; GLUCOSE; PLACEBO; PROLACTIN; TRIACYLGLYCEROL;

ADD ON THERAPY; ADULT; ANXIETY DISORDER; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EXTRAPYRAMIDAL SYMPTOM; FEMALE; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; HEART PALPITATION; HISTORY; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PSYCHOLOGICAL RATING SCALE; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; STATISTICAL SIGNIFICANCE; SYMPTOM; TACHYCARDIA; TREATMENT FAILURE; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 45249113944     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v69n0505     Document Type: Article

References (101)

1. Kane J, Honigfeld G, Singer J, et al. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988;45(9):789-796
2. Lieberman JA, Safferman AZ, Pollack S, et al. Clinical effects of clozapine in chronic schizophrenia: response to treatment and predictors of outcome. Am J Psychiatry 1994;151(12):1744-1752
3. Remington G, Saha A, Chong SA, et al. Augmentation strategies in clozapine-resistant schizophrenia. CNS Drugs 2005;19(10):843-872
4. Lund BC, Perry PJ, Brooks JM, et al. Clozapine use in patients with schizophrenia and the risk of diabetes, hyperlipidemia, and hypertension: a claims-based approach. Arch Gen Psychiatry 2001;58(12):1172-1176
5. Henderson DC, Nguyen DD, Copeland PM, et al. Clozapine, diabetes mellitus, hyperlipidemia, and cardiovascular risks and mortality: results of a 10-year naturalistic study. J Clin Psychiatry 2005;66(9):1116-1121
6. Olfson M, Marcus SC, Corey-Lisle P, et al. Hyperlipidemia following treatment with antipsychotic medications. Am J Psychiatry 2006;163(10):1821-1825
7. Correll CU, Frederickson AM, Kane JM, et al. Does antipsychotic polypharmacy increase the risk for metabolic syndrome? Schizophr Res 2007;89(1-3):91-100
8. Henderson DC, Goff DC. Risperidone as an adjunct to clozapine therapy in chronic schizophrenics. J Clin Psychiatry 1996;57(9):395-397
9. Mowerman S, Siris SG. Adjunctive loxapine in a clozapine-resistant cohort of schizophrenic patients. Ann Clin Psychiatry 1996;8(4):193-197
10. Friedman J, Ault K, Powchik P. Pimozide augmentation for the treatment of schizophrenic patients who are partial responders to clozapine. Biol Psychiatry 1997;42(6):522-523
11. Williams L, Newton G, Roberts K, et al. Clozapine-resistant schizophrenia: a positive approach. Br J Psychiatry 2002;181:184-187
12. Kontaxakis VP, Ferentinos PP, Havaki-Kontaxaki BJ, et al. Randomized controlled augmentation trials in clozapine-resistant schizophrenic patients: a critical review. Eur Psychiatry 2005;20(5-6):409-415
13. Shiloh R, Zemishlany Z, Aizenberg D, et al. Sulpiride augmentation in people with schizophrenia partially responsive to clozapine: a double-blind, placebo-controlled study. Br J Psychiatry 1997;171:569-573
14. Josiassen RC, Joseph A, Kohegyi E, et al. Clozapine augmented with risperidone in the treatment of schizophrenia: a randomized, double-blind, placebo-controlled trial. Am J Psychiatry 2005;162(1):130-136
15. Anil Yagcioglu AE, Kivircik Akdede BB, Turgut TI, et al. A double-blind controlled study of adjunctive treatment with risperidone in schizophrenic patients partially responsive to clozapine: efficacy and safety. J Clin Psychiatry 2005;66(1):63-72
16. Honer WG, Thornton AE, Chen EY, et al. Clozapine alone versus clozapine and risperidone with refractory schizophrenia. N Engl J Med 2006; 354(5):472-482
17. Shapiro DA, Renock S, Arrington E, et al. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology 2003;28(8):1400-1411
18. Davies MA, Sheffler DJ, Roth BL. Aripiprazole: a novel atypical antipsychotic drug with a uniquely robust pharmacology. CNS Drug Rev 2004;10(4):317-336
19. Kikuchi T, Tottori K, Uwahodo Y, et al. 7-(4-[4-(2,3-Dichlorophenyl)-1- piperazinyl]butyloxy)-3,4-dihydro-2(1H)-qui nolinone (OPC-14597), a new putative antipsychotic drug with both presynaptic dopamine auto-receptor agonistic activity and postsynaptic D2 receptor antagonistic activity. J Pharmacol Exp Ther 1995;274(1):329-336
20. Inoue A, Miki S, Seto M, et al. Aripiprazole, a novel antipsychotic drug, inhibits quinpirole-evoked GTPase activity but does not up-regulate dopamine D2 receptor following repeated treatment in the rat striatum. Eur J Pharmacol 1997;321(1):105-111
21. Burris KD, Molski TF, Xu C, et al. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther 2002;302(1):381-389
22. Li Z, Ichikawa J, Dai J, et al. Aripiprazole, a novel antipsychotic drug, preferentially increases dopamine release in the prefrontal cortex and hippocampus in rat brain. Eur J Pharmacol 2004;493(1-3):75-83
23. Zocchi A, Fabbri D, Heidbreder CA. Aripiprazole increases dopamine but not noradrenaline and serotonin levels in the mouse prefrontal cortex. Neurosci Lett 2005;387(3):157-161
24. Pigott TA, Carson WH, Saha AR, et al. Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study. J Clin Psychiatry 2003;64(9):1048-1056
25. Potkin SG, Saha AR, Kujawa MJ, et al. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry 2003;60(7):681-690
26. Marder SR, McQuade RD, Stock E, et al. Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. Schizophr Res 2003;61(2-3):123-136
27. Kasper S, Lerman MN, McQuade RD, et al. Efficacy and safety of aripiprazole vs haloperidol for long-term maintenance treatment following acute relapse of schizophrenia. Int J Neuropsychopharmacol 2003;6(4):325-337
28. Chrzanowski WK, Marcus RN, Torbeyns A, et al. Effectiveness of long-term aripiprazole therapy in patients with acutely relapsing or chronic, stable schizophrenia: a 52-week, open-label comparison with olanzapine. Psychopharmacology (Berl) 2006;189(2):259-266
29. Kane JM, Meltzer HY, Carson WH Jr, et al. Aripiprazole for treatment-resistant schizophrenia: results of a multicenter, randomized, double-blind, comparison study versus perphenazine. J Clin Psychiatry 2007;68(2):213-223
30. De Hert M, Hanssens L, van Winkel R, et al. Reversibility of antipsychotic treatment-related diabetes in patients with schizophrenia: a case series of switching to aripiprazole. Diabetes Care 2006;29(10):2329-2330
31. Lim S, Pralea C, Schnitt J, et al. Possible increased efficacy of low-dose clozapine when combined with aripiprazole [letter]. J Clin Psychiatry 2004;65(9):1284-1285
32. Ziegenbein M, Wittmann G, Kropp S. Aripiprazole augmentation of clozapine in treatment-resistant schizophrenia. Clin Drug Invest 2006;26(3):117-124
33. Henderson DC, Kunkel L, Nguyen DD, et al. An exploratory open-label trial of aripiprazole as an adjuvant to clozapine therapy in chronic schizophrenia. Acta Psychiatr Scand 2006;113(2):142-147
34. Abu-Tair F, Kopitz J, Bergemann N. Clozapine augmented with aripiprazole in 5 patients with schizophrenia. J Clin Psychopharmacol 2006;26(6):669-671
35. Mitsonis CI, Dimopoulos NP, Mitropoulos PA, et al. Aripiprazole augmentation in the management of residual symptoms in clozapine-treated outpatients with chronic schizophrenia: an open-label pilot study. Prog Neuropsychopharmacol Biol Psychiatry 2007;31(2):373-377
36. Rocha FL, Hara C. Benefits of combining aripiprazole to clozapine: three case reports. Prog Neuropsychopharmacol Biol Psychiatry 2006;30(6):1167-1169
37. Clarke LA, Lindenmayer JP, Kaushik S. Clozapine augmentation with aripiprazole for negative symptoms [letter]. J Clin Psychiatry 2006;67(4):675-676
38. Breier A, Buchanan RW, Irish D, et al. Clozapine treatment of outpatients with schizophrenia: outcome and long-term response patterns, 1993. Psychiatr Serv 2000;51(10):1249-1253
39. Fenton WS, McGlashan TH. Natural history of schizophrenia subtypes, 2: positive and negative symptoms and long-term course. Arch Gen Psychiatry 1991;48(11):978-986
40. Buchanan RW, Breier A, Kirkpatrick B, et al. Positive and negative symptom response to clozapine in schizophrenic patients with and without the deficit syndrome. Am J Psychiatry 1998;155(6):751-760
41. Rosenheck R, Dunn L, Peszke M, et al. Impact of clozapine on negative symptoms and on the deficit syndrome in refractory schizophrenia. Am J Psychiatry 1999;156(1):88-93
42. Kane JM, Carson WH, Saha AR, et al. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry 2002;63(9):763-771
43. Birchwood M, Iqbal Z, Chadwick P, et al. Cognitive approach to depression and suicidal thinking in psychosis, 1: ontogeny of post-psychotic depression. Br J Psychiatry 2000;177:516-521
44. Poyurovsky M, Fuchs C, Weizman A. Obsessive-compulsive disorder in patients with first-episode schizophrenia. Am J Psychiatry 1999;156(12):1998- 2000
45. Tollefson GD, Sanger TM, Lu Y, et al. Depressive signs and symptoms in schizophrenia: a prospective blinded trial of olanzapine and haloperidol. Arch Gen Psychiatry 1998;55(3):250-258
46. Conley RR, Ascher-Svanum H, Zhu B, et al. The burden of depressive symptoms in the long-term treatment of patients with schizophrenia. Schizophr Res 2007;90(1-3):186-197
47. Berman I, Kalinowski A, Berman SM, et al. Obsessive and compulsive symptoms in chronic schizophrenia. Compr Psychiatry 1995;36(1):6-10
48. Byerly M, Goodman W, Acholonu W, et al. Obsessive compulsive symptoms in schizophrenia: frequency and clinical features. Schizophr Res 2005;76(2-3):309-316
49. Altamura AC, Bignotti S, Tura G, et al. Depressive symptomatology during clozapine treatment: two case reports. Eur Neuropsychopharmacol 1998;8(3):239-240
50. Baker RW, Chengappa KN, Baird JW, et al. Emergence of obsessive compulsive symptoms during treatment with clozapine. J Clin Psychiatry 1992;53(12):439-442
51. Simon JS, Nemeroff CB. Aripiprazole augmentation of antidepressants for the treatment of partially responding and nonresponding patients with major depressive disorder. J Clin Psychiatry 2005;66(10):1216-1220
52. Papakostas GI, Petersen TJ, Kinrys G, et al. Aripiprazole augmentation of selective serotonin reuptake inhibitors for treatment-resistant major depressive disorder. J Clin Psychiatry 2005;66(10):1326-1330
53. Berman RM, Marcus RN, Swanink R, et al. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2007;68(6):843-853
54. Connor KM, Payne VM, Gadde KM, et al. The use of aripiprazole in obsessive-compulsive disorder: preliminary observations in 8 patients. J Clin Psychiatry 2005;66(1):49-51
55. Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychol Rep 1962;10:799-812
56. Andreasen NC. Scale for the Assessment of Negative Symptoms. Iowa City: University of Iowa; 1983
57. Breier A, Buchanan RW, Kirkpatrick B, et al. Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia. Am J Psychiatry 1994;151(1):20-26
58. Buchanan RW, Kirkpatrick B, Bryant N, et al. Fluoxetine augmentation of clozapine treatment in patients with schizophrenia. Am J Psychiatry 1996;153(12):1625-1627
59. Guy W. ECDEU Assessment Manual for Psychopharmacology. Rev. ed. US Dept Health, Education and Welfare publication (ADM) 76-338. Bethesda, Md: National Institute of Mental Health; 1976:218-222
60. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979;134:382-389
61. Goodman WK, Price LH, Rasmussen SA, et al. The Yale-Brown Obsessive Compulsive Scale, 1: development, use, and reliability. Arch Gen Psychiatry 1989;46(11):1006-1011
62. Naber D, Moritz S, Lambert M, et al. Improvement of schizophrenic patients' subjective well-being under atypical antipsychotic drugs. Schizophr Res 2001;50(1-2):79-88
63. Kirkpatrick B, Fenton WS, Carpenter WT Jr, et al. The NIMH-MATRICS consensus statement on negative symptoms. Schizophr Bull 2006;32(2):214-219
64. Lingjaerde O, Ahlfors UG, Bech P, et al. The UKU side effect rating scale: a new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand Suppl 1987;334:1-100
65. Inada T, Yagi G. Evaluation and Diagnosis of Drug-Induced Extrapyramidal Symptoms: Commentary on the DIEPSS and Guide to Its Usage. Tokyo, Japan: Seiwa Shoten Publishers; 1996
66. Kim JH, Jung HY, Kang UG, et al. Metric characteristics of the Drug-Induced Extrapyramidal Symptoms Scale (DIEPSS): a practical combined rating scale for drug-induced movement disorders. Mov Disord 2002;17(6):1354-1359
67. Inada T, Yagi G, Miura S. Extrapyramidal symptom profiles in Japanese patients with schizophrenia treated with olanzapine or haloperidol. Schizophr Res 2002;57(2-3):227-238
68. Inada T, Beasley CM Jr, Tanaka Y, et al. Extrapyramidal symptom profiles assessed with the Drug-Induced Extrapyramidal Symptom Scale: comparison with Western scales in the clinical double-blind studies of schizophrenic patients treated with either olanzapine or haloperidol. Int Clin Psychopharmacol 2003;18(1):39-48
69. Hsia SH. Non-HDL cholesterol: into the spotlight. Diabetes Care 2003;26(1):240-242
70. Gueorguieva R, Krystal JH. Move over ANOVA: progress in analyzing repeated-measures data and its reflection in papers published in the Archives of General Psychiatry. Arch Gen Psychiatry 2004;61(3):310-317
71. Cohen J. Statistical Power Analysis for the Behavioral Sciences. 2nd ed. Hillsdale, NJ: Lawrence Earlbaum Associates; 1988
72. Freudenreich O, Henderson DC, Walsh JP, et al. Risperidone augmentation for schizophrenia partially responsive to clozapine: a double-blind, placebo-controlled trial. Schizophr Res 2007;92(1-3):90-94
73. DeQuardo JR. Increased efficacy with addition of clozapine to aripiprazole: alternative explanations [letter with reply]. J Clin Psychiatry 2005;66(3):396
74. Karunakaran K, Tungaraza TE, Harborne GC. Is clozapine-aripiprazole combination a useful regime in the management of treatment-resistant schizophrenia? J Psychopharmacol 2007;21(4):453-456
75. Sax KW, Strakowski SM, Keck PE Jr, et al. Relationships among negative, positive, and depressive symptoms in schizophrenia and psychotic depression. Br J Psychiatry 1996;168(1):68-71
76. Fitzgerald PB, Rolfe TJ, Brewer K, et al. Depressive, positive, negative and parkinsonian symptoms in schizophrenia. Aust N Z J Psychiatry 2002;36(3):340-346
77. Kitamura T, Suga R. Depressive and negative symptoms in major psychiatric disorders. Compr Psychiatry 1991;32(1):88-94
78. Chemerinski E, Reichenberg A, Kirkpatrick B, et al. Three dimensions of clinical symptoms in elderly patients with schizophrenia: prediction of six-year cognitive and functional status. Schizophr Res 2006;85(1-3):12-19
79. Potkin SG, Alva G, Fleming K, et al. A PET study of the pathophysiology of negative symptoms in schizophrenia: positron emission tomography. Am J Psychiatry 2002;159(2):227-237
80. Murphy BP, Chung YC, Park TW, et al. Pharmacological treatment of primary negative symptoms in schizophrenia: a systematic review. Schizophr Res 2006;88(1-3):5-25
81. Fenton WS, McGlashan TH. Natural history of schizophrenia subtypes, 1: longitudinal study of paranoid, hebephrenic, and undifferentiated schizophrenia. Arch Gen Psychiatry 1991;48(11):969-977
82. Deister A, Marneros A. Prognostic value of initial subtype in schizophrenic disorders. Schizophr Res 1994;12(2):145-157
83. Rosenheck R, Dunn L, Peszke M, et al. Impact of clozapine on negative symptoms and on the deficit syndrome in refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia. Am J Psychiatry 1999;156(1):88-93
84. Ventura J, Nuechterlein KH, Green MF, et al. The timing of negative symptom exacerbations in relationship to positive symptom exacerbations in the early course of schizophrenia.Schizophr Res 2004;69(2-3):333-342
85. Yokoi F, Grunder G, Biziere K, et al. Dopamine D2 and D3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC 14597): a study using positron emission tomography and [11C]raclopride. Neuropsychopharmacology 2002;27(2):248-259
86. Karow A, Moritz S, Lambert M, et al. PANSS syndromes and quality of life in schizophrenia. Psychopathology 2005;38(6):320-326
87. Reine G, Lançon C, Di Tucci S, et al. Depression and subjective quality of life in chronic phase schizophrenic patients. Acta Psychiatr Scand 2003;108(4):297-303
88. Ho BC, Nopoulos P, Flaum M, et al. Two-year outcome in first-episode schizophrenia: predictive value of symptoms for quality of life. Am J Psychiatry 1998;155(9):1196-1201
89. Poyurovsky M, Weizman A, Weizman R. Obsessive-compulsive disorder in schizophrenia: clinical characteristics and treatment. CNS Drugs 2004;18(14):989-1010
90. Knegtering H, van der Moolen AE, Castelein S, et al. What are the effects of antipsychotics on sexual dysfunctions and endocrine functioning? Psychoneuroendocrinology 2003;28(suppl 2):109-123
91. Ben-Jonathan N, Hugo ER, Brandebourg TD, et al. Focus on prolactin as a metabolic hormone. Trends Endocrinol Metab 2006;17(3):110-116
92. Lamberti JS, Costea GO, Olson D, et al. Diabetes mellitus among outpatients receiving clozapine: prevalence and clinical-demographic correlates. J Clin Psychiatry 2005;66(7):900-906
93. Austin MA, Hokanson JE, Edwards KL. Hypertriglyceridemia as a cardiovascular risk factor. Am J Cardiol 1998;81(4A):7B-12B
94. Gaulin BD, Markowitz JS, Caley CF, et al. Clozapine-associated elevation in serum triglycerides. Am J Psychiatry 1999;156(8):1270-1272
95. Cui Y, Blumenthal RS, Flaws JA, et al. Non-high-density lipoprotein cholesterol level as a predictor of cardiovascular disease mortality. Arch Intern Med 2001;161(11):1413-1419
96. Rubies-Prat J, Reverter JL, Senti M, et al. Calculated low-density lipoprotein cholesterol should not be used for management of lipoprotein abnormalities in patients with diabetes mellitus. Diabetes Care 1993;16(8):1081-1086
97. Matsuda KT, Cho MC, Lin KM, et al. Clozapine dosage, serum levels, efficacy, and side-effect profiles: a comparison of Korean-American and Caucasian patients. Psychopharmacol Bull 1996;32(2):253-257
98. Ng CH, Chong SA, Lambert T, et al. An inter-ethnic comparison study of clozapine dosage, clinical response and plasma levels. Int Clin Psychopharmacol 2005;20(3):163-168
99. Subramaniam M, Ng C, Chong SA, et al. Metabolic differences between Asian and Caucasian patients on clozapine treatment. Hum Psychopharmacol 2007;22(4):217-222
100. Senn S. Are placebo run-ins justified? BMJ 1997;314(7088): 1191-1193
101. Lee S, Walker JR, Jakul L, et al. Does elimination of placebo responders in a placebo run-in increase the treatment effect in randomized clinical trials? a meta-analytic evaluation. Depress Anxiety 2004;19(1):10-19